Follow us on Facebook!
Follow us on Twitter!
Follow us on Youtube!

News archive

Recent news

 

The randomized, placebo-controlled, double-blind Phase 3 clinical trial TOURMALINE-MM4 showed significant improvement in Progression-Free Survival (PFS) of Ixazomib (commercialised by Takeda as Ninlaro) as first line maintenance therapy versus placebo in adult myeloma patients not treated with stem cell transplantation. This clinical trial is the first industry sponsored phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting. Continue reading

 

The professional society for health economics and outcomes research, ISPOR, organises its annual meeting in Copenhagen, Denmark. From 2 to 6 November experts attending this meeting will debate value in healthcare beyond cost-containment and short-term interventions. Continue reading

More than 3.900 abstracts have been submitted to the European Society for Medical Oncology Congress (ESMO) Annual Congress which will be held from 27 September to 1st October 2019 in Barcelona, Spain. Continue reading

 

European Commission (EC) has approved elotuzumab  –marketed under the brand Empliciti by Bristol-Myers Squibb (BMS)– plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy. Continue reading

 

With the aim of addressing common educational needs of the cancer advocacy community, the Workgroup of European Cancer Patient Advocacy Networks (WECAN) held the first WECAN Academy from 6-9 July 2019 in Frankfurt, Germany. Continue reading

1 2 3 16